Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis.

Adv Radiat Oncol · 2017 · PMC5605486 · PMID 29114614

Europe PMC DOI

hedged sentences

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

showed a trendP = .12not close (p > 0.1)

CB patients also showed a trend toward higher 5 and 10 year regional control rates compared with SD patients (97.7% and 97.7% vs 97.1% and 82.9%, respectively; P = .12 for both) at 5 and 10 years, respectively.

also in 53,322 other papers

highly significantno p-value reported

7 Other researchers have reported a highly significant dose-response relationship for patients with LARC after neoadjuvant CRT for dose levels in the range of 50.4 to 70 Gy, notably higher than a conventional dose. 7 Additionally, the efficacy and safety of dose escalation delivered using both EBRT and/or brachytherapy in LARC has been reported by seve

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.